TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07531745: ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome

Sponsor: Ionis Pharmaceuticals, Inc. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 32 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$931,260

Rescue Site Savings

+$620,840

Unlock Full NCT07531745 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07531745 Rescue Dossier →